MotorGraft Clinical Trial for SMA Placed on FDA Clinical Hold
FSMA Press Release | February 8, 2011
In December, California Stem Cell, Inc. (CSC) announced that CSC filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy (SMA) Type I. Recently, CSC received an official response from the FDA. As anticipated the trial is on clinical hold. A summary of that FDA response from CSC is shown below.
California Stem Cell’s MotorGraft trial for the treatment of spinal muscular atrophy (SMA) has been placed on clinical hold by the Food and Drug Administration (FDA). A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial. Clinical holds are not uncommon, especially in cases of novel treatments such as this one. Similar holds were issued by the FDA to each of the previous applications for pluripotent stem cell therapeutics, such as those submitted by NeuralStem (ALS trial), Geron Corporation (spinal cord injury trial) and Advanced Cell Technology (macular degeneration trial), and all have since been lifted and advanced to clinical trials.
Click HERE or on the image below to read more…